MedTrace Logo

ENvarsus for Impaired Glucose Tolerance Post REnal transplAnT

NCT04973982 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-04-01

No results posted yet for this study

Summary

Our hypothesis is that switching from the current standard of care twice daily Adoport (Tacrolimus) to once daily Envarsus (tacrolimus) in patients who have impaired glucose tolerance post-transplant will lead to an improvement in their glucose tolerance, and may reduce the subsequent incidence of PTDM.

Conditions

  • Renal Transplant Failure

Interventions

DRUG

Envarsus

3 month treatment, given once daily, oral tablet. Dose titrated according to levels target 6-10ng/ml

DRUG

Adoport

3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml

Sponsors & Collaborators

  • Barts & The London NHS Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2022-08-01
Completion
2022-10-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04973982 on ClinicalTrials.gov